cefixime has been researched along with Bacteremia in 7 studies
Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.
Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cefixime seems to be an acceptable alternative to the regimens containing an aminopenicillin and an aminoglycoside for the treatment of community-acquired non-complicated APN." | 6.69 | [Cefixime versus amoxicillin plus netilmicin in the treatment of community-acquired non-complicated acute pyelonephritis]. ( Almela, M; García San Miguel, J; Marco, F; Martínez, JA; Mensa, J; Moreno-Martínez, A; Soriano, E; Vila, J, 1998) |
| " One child developed bacteremia 3 days after completing the course of cefixime, and one had splenic sequestration on the fourth study day." | 5.08 | Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease. ( Dancy, RM; Day, SW; Harris, SC; Wang, WC; Wilimas, JA; Williams, LL, 1996) |
| "Recently, the cefixime-ofloxacin combination is approved by Drug Controller General of India to treat typhoid fever." | 3.85 | In vitro efficacy and in silico analysis of cefixime-ofloxacin combination for Salmonella Typhi from bloodstream infection. ( Babu, P; Bakthavatchalam, YD; Doss, CGP; Kumar, DT; Munusamy, E; Ravi, R; Shankar, BA; Tayubi, IA; Thukkaram, B; Veeraraghavan, B, 2017) |
| "Cefixime seems to be an acceptable alternative to the regimens containing an aminopenicillin and an aminoglycoside for the treatment of community-acquired non-complicated APN." | 2.69 | [Cefixime versus amoxicillin plus netilmicin in the treatment of community-acquired non-complicated acute pyelonephritis]. ( Almela, M; García San Miguel, J; Marco, F; Martínez, JA; Mensa, J; Moreno-Martínez, A; Soriano, E; Vila, J, 1998) |
| "Cefixime (7." | 2.68 | Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children. ( Farid, Z; Girgis, NI; Hammad, O; Sultan, Y, 1995) |
| " Ceftazidime, cefepime, and piperacillin-tazobactam in combination with amikacin showed greater activity than found in combination with ciprofloxacin." | 1.42 | In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia. ( Cha, MK; Cho, SY; Chung, DR; Ha, YE; Kang, CI; Kim, SH; Peck, KR; Song, JH; Wi, YM, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakthavatchalam, YD | 1 |
| Kumar, DT | 1 |
| Tayubi, IA | 1 |
| Shankar, BA | 1 |
| Babu, P | 1 |
| Munusamy, E | 1 |
| Thukkaram, B | 1 |
| Ravi, R | 1 |
| Doss, CGP | 1 |
| Veeraraghavan, B | 1 |
| Carannante, N | 1 |
| Pallotto, C | 1 |
| Bernardo, M | 1 |
| Mallardo, E | 1 |
| Di Caprio, G | 1 |
| Palmiero, G | 1 |
| Attanasio, V | 1 |
| Tascini, C | 1 |
| Sultan, BA | 1 |
| Fasih, N | 1 |
| Qaiser, S | 1 |
| Khan, E | 1 |
| Zafar, A | 1 |
| Irfan, S | 1 |
| Cha, MK | 1 |
| Kang, CI | 1 |
| Kim, SH | 1 |
| Cho, SY | 1 |
| Ha, YE | 1 |
| Wi, YM | 1 |
| Chung, DR | 1 |
| Peck, KR | 1 |
| Song, JH | 1 |
| Girgis, NI | 1 |
| Sultan, Y | 1 |
| Hammad, O | 1 |
| Farid, Z | 1 |
| Williams, LL | 1 |
| Wilimas, JA | 1 |
| Harris, SC | 1 |
| Day, SW | 1 |
| Dancy, RM | 1 |
| Wang, WC | 1 |
| Moreno-Martínez, A | 1 |
| Mensa, J | 1 |
| Martínez, JA | 1 |
| Marco, F | 1 |
| Vila, J | 1 |
| Almela, M | 1 |
| García San Miguel, J | 1 |
| Soriano, E | 1 |
3 trials available for cefixime and Bacteremia
| Article | Year |
|---|---|
Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children.
Topics: Adolescent; Anti-Bacterial Agents; Aztreonam; Bacteremia; Cefixime; Cefotaxime; Ceftriaxone; Cephalo | 1995 |
Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Anti-Infective Agents; Bacteremia; Bacterial | 1996 |
[Cefixime versus amoxicillin plus netilmicin in the treatment of community-acquired non-complicated acute pyelonephritis].
Topics: Acute Disease; Adult; Aged; Amoxicillin; Bacteremia; Cefixime; Cefotaxime; Cephalosporins; Communica | 1998 |
4 other studies available for cefixime and Bacteremia
| Article | Year |
|---|---|
In vitro efficacy and in silico analysis of cefixime-ofloxacin combination for Salmonella Typhi from bloodstream infection.
Topics: Anti-Bacterial Agents; Bacteremia; Cefixime; Humans; India; Microbial Sensitivity Tests; Ofloxacin; | 2017 |
Breakthrough pneumonia, meningitis and bloodstream infection due to
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacteremia; Cefixime; Female; Humans; Incidence; Italy; Ma | 2019 |
Mixed Salmonella infection: a report of two cases from the Aga Khan University Hospital, Karachi.
Topics: Anti-Bacterial Agents; Bacteremia; Cefixime; Ceftriaxone; Child, Preschool; Female; Fever; Humans; M | 2013 |
In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cefixime; Ceftazidime; Escheric | 2015 |